NCT04375267 2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1 Completed
Clinical Trials
6 trialsNCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT04394858 2026-04-13
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04086485 2026-04-07
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05870423 2025-06-05
PRRT-PARPi
Erasmus Medical Center
Phase 1 Recruiting
NCT04538378 2025-01-27
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated